-
BioCryst to Host Conference Call & Web cast Today at 6:30 p.m.
Eastern Time
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the
presentation of new data related to the efficacy and safety of BCX4208
for the treatment of gout at the 74th ACR Scientific Meeting
being held in Atlanta, Georgia.
The data will be presented during a poster session scheduled for today,
November 8, 2010 from 9:00-11:00 a.m. Eastern Time. The poster to be
presented during the session is entitled:
-
"Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on
the Serum Uric Acid Concentrations in Patients with Gout". This poster
concludes that BCX4208 doses administered at 40, 80, 120, 160 and 240
mg once-daily monotherapy rapidly and significantly reduced serum uric
acid (sUA) in patients with gout. BCX4208 was generally safe and
well-tolerated at the doses evaluated in this study.
Conference Call and Web Cast
BioCryst will host a conference call and Web cast today at 6:30 p.m.
Eastern Time where a summary of the new BCX4208 data presented at ACR
will be reviewed by Dr. William Sheridan, Chief Medical Officer at
BioCryst, and commentary regarding gout prevalence and patient
demographics as well as current and emerging treatment options will be
provided by Dr. Robert Terkeltaub, VA Rheumatology Section Chief, San
Diego Professor of Medicine.
To participate in the conference call, please dial 1-877-303-8027
(United States) or 1-760-536-5165 (International). No passcode is needed
for the call. The Web cast can be accessed by logging onto http://www.biocryst.com.
Please connect to the Web site at least 15 minutes prior to the start of
the conference call to ensure adequate time for any software download
that may be necessary.
About BCX4208
BCX4208 is a next generation purine nucleoside phosphorylase (PNP)
inhibitor with the potential for once-a-day dosing suitable for chronic
administration. With its unique mechanism of action, clinical activity
and safety in clinical studies to date as well as its potential synergy
with approved therapies, BCX4208 has the potential to address unmet
medical needs across a broad spectrum of inflammatory and autoimmune
diseases. In September 2010, BioCryst reported positive results from its
Phase 2 study of BCX4208 alone and in combination with allopurinol in
patients with gout, announcing that the study met its primary endpoint
related to serum uric acid (sUA) reduction, demonstrated a dose-response
for both BCX4208 and allopurinol, and that the combination of BCX4208
and allopurinol was shown to be superior to either drug alone in sUA
reduction. For more information about BCX4208 please visit BioCryst's
Web site at http://www.biocryst.com/bcx_4208.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development:
peramivir, a neuraminidase inhibitor for the treatment of influenza,
BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the
treatment of gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early
development to address the unmet medical needs of patients and
physicians. For more information, please visit the Company's Web site at www.biocryst.com.
Forward-Looking Statements
This press release contains forward-looking statements, including
statements regarding future results, performance or achievements. These
statements involve known and unknown risks, uncertainties and other
factors which may cause our actual results, performance or achievements
to be materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
These statements reflect our current views with respect to future events
and are based on assumptions and subject to risks and uncertainties.
Given these uncertainties, you should not place undue reliance on these
forward-looking statements. Some of the factors that could affect the
forward-looking statements contained herein include: that ongoing and
future pre-clinical and clinical development of BCX4208 may not have
positive results; that we or our licensees may not be able to enroll the
required number of subjects in planned clinical trials of our product
candidates and that such clinical trials may not be successfully
completed; that BioCryst or its licensees may not commence as expected
additional human clinical trials with our product candidates; that our
product candidates may not receive required regulatory clearances from
the FDA; that ongoing and future pre-clinical and clinical development
may not have positive results; that we or our licensees may not be able
to continue future development of our current and future development
programs; that our development programs may never result in future
product, license or royalty payments being received by BioCryst; that
BioCryst may not be able to retain its current pharmaceutical and
biotechnology partners for further development of its product candidates
or it may not reach favorable agreements with potential pharmaceutical
and biotechnology partners for further development of its product
candidates; that our actual cash burn rate may not be consistent with
our expectations; that BioCryst may not have sufficient cash to continue
funding the development, manufacturing, marketing or distribution of its
products and that additional funding, if necessary, may not be available
at all or on terms acceptable to BioCryst. Please refer to the documents
BioCryst files periodically with the Securities and Exchange Commission,
specifically BioCryst's most recent Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of
which identify important factors that could cause the actual results to
differ materially from those contained in our projections and
forward-looking statements.
BCRXW
BioCryst Pharmaceuticals
Investors:
Robert Bennett,
+1-919-859-7910
or
WCG
Media:
Catherine Collier
Kyroulis, +1-212-301-7174
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media